410 related articles for article (PubMed ID: 15858808)
1. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
Colombo C; Costantini D; Rocchi A; Cariani L; Garlaschi ML; Tirelli S; Calori G; Copreni E; Conese M
Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
[TBL] [Abstract][Full Text] [Related]
2. Cytokine pattern in cystic fibrosis patients during antibiotic therapy and gene therapy using adenoviral vector.
Reix P; Bellon G; Bienvenu J; Pavirani A; Levrey-Hadden H
Eur Cytokine Netw; 2002; 13(3):324-30. PubMed ID: 12231476
[TBL] [Abstract][Full Text] [Related]
3. Production of the potent neutrophil chemokine, growth-related protein alpha (GROalpha), is not elevated in cystic fibrosis children.
Wyatt HA; Sampson AP; Balfour-Lynn IM; Price JF
Respir Med; 2000 Feb; 94(2):106-11. PubMed ID: 10714414
[TBL] [Abstract][Full Text] [Related]
4. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis.
Cunningham S; McColm JR; Mallinson A; Boyd I; Marshall TG
Pediatr Pulmonol; 2003 Jul; 36(1):43-8. PubMed ID: 12772222
[TBL] [Abstract][Full Text] [Related]
5. Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy.
Chiron R; Grumbach YY; Quynh NV; Verriere V; Urbach V
J Cyst Fibros; 2008 Nov; 7(6):463-8. PubMed ID: 18541460
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
[TBL] [Abstract][Full Text] [Related]
7. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis.
Sagel SD; Kapsner RK; Osberg I
Pediatr Pulmonol; 2005 Mar; 39(3):224-32. PubMed ID: 15635615
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
[TBL] [Abstract][Full Text] [Related]
9. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients.
Hansen CR; Pressler T; Nielsen KG; Jensen PØ; Bjarnsholt T; Høiby N
J Cyst Fibros; 2010 Jan; 9(1):51-8. PubMed ID: 19939747
[TBL] [Abstract][Full Text] [Related]
10. Association between inflammatory markers in induced sputum and clinical characteristics in children with non-cystic fibrosis bronchiectasis.
Guran T; Ersu R; Karadag B; Akpinar IN; Demirel GY; Hekim N; Dagli E
Pediatr Pulmonol; 2007 Apr; 42(4):362-9. PubMed ID: 17351928
[TBL] [Abstract][Full Text] [Related]
11. Effects of a short-term rehabilitation program on airway inflammation in children with cystic fibrosis.
Moeller A; Stämpfli SF; Rueckert B; Rechsteiner T; Hamacher J; Wildhaber JH
Pediatr Pulmonol; 2010 Jun; 45(6):541-51. PubMed ID: 20503278
[TBL] [Abstract][Full Text] [Related]
12. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function.
Eickmeier O; Huebner M; Herrmann E; Zissler U; Rosewich M; Baer PC; Buhl R; Schmitt-Grohé S; Zielen S; Schubert R
Cytokine; 2010 May; 50(2):152-7. PubMed ID: 20181491
[TBL] [Abstract][Full Text] [Related]
13. Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers.
Smountas AA; Lands LC; Mohammed SR; Grey V
Clin Biochem; 2004 Nov; 37(11):1031-6. PubMed ID: 15498533
[TBL] [Abstract][Full Text] [Related]
14. Lipopolysaccharide (LPS), LPS-immune complexes and cytokines as inducers of pulmonary inflammation in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
Kronborg G
APMIS Suppl; 1995; 50():1-30. PubMed ID: 7756034
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease.
Pukhalsky AL; Shmarina GV; Kapranov NI; Kokarovtseva SN; Pukhalskaya D; Kashirskaja NJ
Mediators Inflamm; 2004 Apr; 13(2):111-7. PubMed ID: 15203552
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal of inhaled steroids in children with non-cystic fibrosis bronchiectasis.
Guran T; Ersu R; Karadag B; Karakoc F; Demirel GY; Hekim N; Dagli E
J Clin Pharm Ther; 2008 Dec; 33(6):603-11. PubMed ID: 19138237
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of home treatment for patients with cystic fibrosis: the intravenous administration of antibiotics to treat respiratory infections.
Termoz A; Touzet S; Bourdy S; Decullier E; Bouveret L; Colin C; Nove-Josserand R; Reix P; Cracowski C; Pin I; Bellon G; Durieu I
Pediatr Pulmonol; 2008 Sep; 43(9):908-15. PubMed ID: 18680182
[TBL] [Abstract][Full Text] [Related]
18. Cellular proteolysis and systemic inflammation during exacerbation in cystic fibrosis.
Ionescu AA; Nixon LS; Shale DJ
J Cyst Fibros; 2004 Dec; 3(4):253-8. PubMed ID: 15698944
[TBL] [Abstract][Full Text] [Related]
19. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
[TBL] [Abstract][Full Text] [Related]
20. Exhaled breath condensate pH and ammonia in cystic fibrosis and response to treatment of acute pulmonary exacerbations.
Newport S; Amin N; Dozor AJ
Pediatr Pulmonol; 2009 Sep; 44(9):866-72. PubMed ID: 19670404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
